Radioisotope Production (Radium-223)

Ra-223 decays by alpha emission with a half-life of 11.4 days. It is typically produced from actinium-225 or thorium-229 decay chains. The resulting Ra-223 is then chemically separated and incorporated into radiopharmaceuticals. Supply chain considerations involve the availability of actinium or thorium sources and radiochemistry facilities. Logistical challenges include the transport and handling of radioactive materials, particularly alpha emitters. Accessibility for developing countries is influenced by the specialised facilities and regulatory requirements.

Ra-223 production and application are well-established, with use in targeted alpha therapy.

Ra-233 is a radioactive isotope that emits alpha radiation, requiring careful handling procedures and physical shielding to minimise radiation exposure.

All radioactive isotopes can be misused, and as such, robust security protocols around chain of custody, inventory management, and physical security are critical.

Due to the absence of nuclear materials, IAEA safeguards are not applicable.